Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Authorities okay launch of phase Ib/II human clinical trial for anticancer drug CTCE-9908
March 9th, 2006
Chemokine Therapeutics Corp. (CHKT), a biotechnology company developing drugs in the field of chemokines, announced that it has received approval from Health Canada to initiate a phase Ib/II clinical trial using CTCE-9908, a chemokine CXCR4 antagonist. With this notice, the company is now in a position to initiate the clinical trial. The company plans to test the drug in up to 30 patients with late-stage cancers to evaluate safety as well as early efficacy. The trial is designed to study a mixed group of tumors that will include the most common cancers such as ovarian, lung, and breast. Chemokine expects to expand its CTCE-9908 clinical program with...
Source: Women's Health Weekly (2006-03-09)
|
